Get the Stockscreener App
8.91
9.19%
0.75
Pre-market:
8.91
Emergent Biosolutions Inc stock is traded at $8.91, with a volume of 1.94M.
It is up +9.19% in the last 24 hours and up +21.06% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$8.16
Open:
$8.24
24h Volume:
1.94M
Relative Volume:
1.42
Market Cap:
$475.36M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.6037
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
+46.07%
1M Performance:
+21.06%
6M Performance:
-5.91%
1Y Performance:
+33.58%
1-Day Range:
$8.24
$9.13
1-Week Range:
$6.03
$9.28
52-Week Range:
$4.02
$13.28
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.91 | 435.34M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
149.77 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.63 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.58 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.60 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.39 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions’ Strong Q2 Fuels Hopes for 2025 Rally - citybiz
300 new jobs headed to Bayview manufacturing plant - The Business Journals
Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally - Seeking Alpha
Emergent BioSolutions Reports Improved Q2 2025 Results - TipRanks
Published on: 2025-08-10 18:27:00 - metal.it
Earnings Update: Here's Why Analysts Just Lifted Their Emergent BioSolutions Inc. (NYSE:EBS) Price Target To US$13.50 - simplywall.st
Emergent BioSolutions Inc. (NYSE:EBS) Q2 2025 Earnings Call Transcript - Insider Monkey
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates - MSN
Emergent BioSolutions' Strong ROE Amid Industry Average: A Financial Analysis - AInvest
Can Emergent BioSolutions Inc. (NYSE:EBS) Maintain Its Strong Returns? - Yahoo Finance
Emergent BioSolutions to participate in investor conferences in May and June 2025. - AInvest
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Emergent BioSolutions Exceeds Q2 Revenue Guidance, Raises Full-Year Profitability Guidance - AInvest
BioPharma Co.'s $15M Deal Over Ruined J&J Vaccines OK'd - Law360
Emergent BioSolutions Surpasses Q2 Revenue Expectations - The Globe and Mail
Emergent BioSolutions reports Q2 adjusted EPS 16c vs ($2.32) last year - TipRanks
Emergent BioSolutions Soars 22% on Earnings Surprise: What's Fueling the Surge? - AInvest
Emergent Biosolutions reports second quarter loss - Maryland Daily Record
Emergent Biosolutions shares rise 6.14% premarket after securing $51.9 million contract modification for smallpox preparedness. - AInvest
Installed Building Products reports record Q2 2025 results, 3.1% revenue increase. - AInvest
Emergent Biosolutions Q2 Earnings Report: $12 Million LossNews and Statistics - IndexBox
Emergent Biosolutions: Q2 Earnings Snapshot - Huron Daily Tribune
Emergent BioSolutions Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Emergent BioSolutions Q2 2025 results show mixed performance - Investing.com
Emergent BioSolutions Outpaces Its Own Forecasts But Misses Analyst Targets - Finimize
Emergent Biosolutions earnings beat by $0.26, revenue fell short of estimates - Investing.com Canada
Emergent BioSolutions Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Emergent BioSolutions Q2 revenue misses analyst expectations - MarketScreener
Emergent BioSolutions Q2 2025 slides: Profitability improves as transformation continues - Investing.com Canada
Emergent Biosolutions Q2 Earnings: Non-GAAP EPS Beats by $0.65, Revenue Misses by $5.47M - AInvest
Emergent BioSolutions Reports Second Quarter 2025 Financial Results - The Manila Times
Emergent BioSolutions Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
What drives Emergent BioSolutions Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
Is it the right time to buy Emergent BioSolutions Inc. stockMaximize your portfolio’s growth potential - Jammu Links News
How many analysts rate Emergent BioSolutions Inc. as a “Buy”Strong return on assets - Jammu Links News
What catalysts could drive Emergent BioSolutions Inc. stock higher in 2025Access high-yield investment alerts now - Jammu Links News
Is Emergent BioSolutions Inc. stock overvalued or undervaluedTriple returns potential - Jammu Links News
Why is Emergent BioSolutions Inc. stock attracting strong analyst attentionInvest smarter and grow your wealth faster - Jammu Links News
What are the technical indicators suggesting about Emergent BioSolutions Inc.Stock Market Ideas With Proven Results - Jammu Links News
Insider Sellers Might Regret Selling Emergent BioSolutions Shares at a Lower Price Than Current Market Value - simplywall.st
What institutional investors are buying Emergent BioSolutions Inc. stockPost Market Outlook For Every Investor - Jammu Links News
Why Emergent BioSolutions Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - beatles.ru
Can Emergent BioSolutions Inc. recover in the next quarterReal-Time Analysis With Entry Targets In Progress - metal.it
Emergent BioSolutions Inc. Recovery Hinges on Volume BreakoutPotential Breakout Stock List Published This Week - metal.it
Investors Hope for Bounce in Emergent BioSolutions Inc. After SelloffAI Based High Gain Watchlist Scanner Shared - metal.it
Can Emergent BioSolutions Inc. Regain Momentum After BreakdownCapital Growth With Controlled Risk Picks Suggested - metal.it
Published on: 2025-07-29 03:10:46 - metal.it
Emergent BioSolutions (EBS) Applauds Naloxone Accessibility in U - GuruFocus
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - The Manila Times
Emergent BioSolutions Commends U.S. House of Representatives for Naloxone Accessibility Initiative - Quiver Quantitative
U.S. House Takes Historic Step: NARCAN Now Available in Every Building to Prevent Opioid Deaths - Stock Titan
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):